Adze Biotechnology Australia

Adze Biotechnology is a clinical-stage biopharmaceutical company focused on the development of next-generation oncolytic virus therapies for oncology. The company's lead candidate, ADZ-001, is an engineered adenovirus designed to selectively infect and lyse cancer cells while triggering a robust systemic immune response against the tumor. Adze Biotechnology Australia Pty Ltd serves as the company's clinical operations hub, leveraging Australia's efficient regulatory environment to conduct early-phase human trials. The company's proprietary platform allows for the engineering of viruses with enhanced tumor selectivity and potent immune-stimulating capabilities. By combining direct viral oncolysis with immunotherapy, Adze aims to provide new treatment options for patients with advanced solid tumors that are resistant to standard therapies.